IBIO

iBio, Inc.

2.10 USD
-0.01 (-0.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

iBio, Inc. stock is down -5.63% since 30 days ago. The next earnings date is Sep 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 13 June’s closed higher than May. 100% of analysts rate it a buy.

About iBio, Inc.

iBio, Inc. provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.

  • Chardan Capital
    Mon Jun 3, 15:47
    buy
    confirm
  • Chardan Capital
    Tue May 28, 06:44
    buy
    initial